Mark Holck - Concepedia

Author

Mark Holck

Roche (Switzerland)

Also Known As

M Holck, M I Holck, M. HOLCK, M. Holck, M. I. HOLCK, M. I. Holck, M.I. Holck, MARK I. HOLCK, Mark Holck, Mark I. Holck

Publications

652

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)

About

Mark Holck is an author at Roche (Switzerland) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	430
2	Social Sciences	2	2	28
3	Anesthesia	2	2	89
4	Biochemistry	2	2	95
5	Engineering	1	1	23

Mark Holck

Publications

639

Citations

H-Index

Page 1

	Year	Citations
In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic Action Wolfgang Osterrieder, Mark Holck Journal of Cardiovascular Pharmacology	1989	101
In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic Action Wolfgang Osterrieder, Mark Holck Journal of Cardiovascular Pharmacology Cardiovascular PharmacologyPotent VasodilatorVitro Pharmacologic ProfilePharmacotherapyCardiovascular Function	1989	90
Purine nucleoside and nucleotide interactions on normal and subsensitive alpha adrenoreceptor responsiveness in guinea-pig vas deferens. Mark Holck, Bernard H. Marks Journal of Pharmacology and Experimental Therapeutics	1978	82
Characterization of [3H]nifedipine binding sites in rabbit myocardium Mark Holck, Sébastien Thorens, Guenther Haeusler European Journal of Pharmacology Molecular PharmacologyCardiac MuscleMolecular PhysiologyBiochemistryPhysiology	1982	73
Differential Interactions of Clonidine and Methoxamine with the Postsynaptic α-Adrenoceptor of Rabbit Main Pulmonary Artery Mark Holck, C. Jones, G. Haeusler Journal of Cardiovascular Pharmacology Molecular PharmacologyPulmonary Arterial HypertensionPulmonary CirculationMedicineVascular Pharmacology	1983	62
The peripheral high affinity benzodiazepine binding site is not coupled to the cardiac Ca2+ channel Mark Holck, Wolfgang Osterrieder European Journal of Pharmacology Cardiac MuscleMedicinePhysiologyIon ChannelsCardiac Ca2+ Channel	1985	47
Cardiovascular Effects of the New Angiotensin-Converting-Enzyme Inhibitor, Cilazapril, in Anesthetized and Conscious Dogs Mark Holck, Walter Fischli, Franz Hefti, Journal of Cardiovascular Pharmacology HypertensionCardiac AnaesthesiaCardiovascular PharmacologyPharmacotherapyBlood Pressure	1986	27
Interaction of the Cardiotonic Agent DPI 201-106 with Cardiac Ca2+ Channels Mark Holck, Wolfgang Osterrieder Journal of Cardiovascular Pharmacology Cardiac MuscleHeart FailureEngineeringCardiotonic Agent DpiCardiac Ca2+ Channels	1988	23
(−)‐<i>N</i>‐[(Cyclopropyl) methyl]‐3,4‐dimethoxy‐5‐methylmorphinan‐6‐one, an opioid agonist with preference for kappa opioid receptors Helmut Schmidhammer, Florian Fritsch, Willy P. Burkard, Helvetica Chimica Acta Opioid EpidemicMolecular PharmacologyEssential IntermediatePharmaceutical ChemistryBiochemistry	1988	22
An angiotensin II antagonist with strongly prolonged action Mark Holck, Roger Bossé, Walter Fischli, Biochemical and Biophysical Research Communications Molecular PharmacologyHypertensionMedicineAntihypertensive TherapyCardiovascular Pharmacology	1989	20

Page 1